BLTI Biolase Technology, Inc. (MM)

BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that the new line of Waterlase MDX™ all-tissue lasers was launched this week at the annual Chicago Dental Society Midwinter Meeting being held through February 25 (Booth #1237). The new Waterlase MDX lasers expand the Company's product offerings and complement the industry-leading Waterlase iPlus™ all-tissue dental laser system.

Two models of the Waterlase MDX are available. The 8-watt Waterlase MDX 300 improves on BIOLASE's time-tested Waterlase MD platform with an updated user interface, a new laser engine and a new lightweight and more flexible titanium fiber cable. The Waterlase MDX 450 increases the power output to 9-watts and cuts hard-tissue up to 70 percent faster than the Waterlase MDX 300, but is still approximately 40 percent slower than the Waterlase iPlus.

"The new Waterlase MDX again demonstrates our engineering expertise and ability to design products for all segments of the global dental market," said Chairman and CEO Federico Pignatelli. "Our flagship laser, the Waterlase iPlus, is the most advanced laser ever produced for dentistry and, with its tremendous cutting speed and graphical intuitive user interface, addresses a wide range of clinical procedures with more than 50 presets. The new Waterlase MDX is the logical evolution of the Waterlase MD Turbo, the best selling all-tissue dental laser in history, and allows us to offer a blend of features from the Waterlase iPlus and Waterlase MD in a modernized platform to practitioners that do not require the advanced speed and functionality of the Waterlase iPlus.

"The Waterlase MDX has been very well received upon its introduction at the Chicago Midwinter show and we see it adding a new dimension to our comprehensive line of laser dental products," concluded Pignatelli.

Dmitri Boutoussov, Chief Technology Officer, commented, "We wanted to build on our well established Waterlase MD platform and integrate our finest laser engine technology to that product. This allows us to offer the Waterlase MDX in multiple power configurations to meet the price and performance needs of specialists such as endodontists and pediatric dentists whose clinical indications do not require the features and performance of the Waterlase iPlus."

About BIOLASE Technology, Inc. BIOLASE Technology, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate 284 patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,000 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: Jill Bertotti Allen & Caron +1-949-474-4300 jill@allencaron.com